Revisiting determinants of prognosis in cutaneous melanoma

Cancer

Volumn 121, Issue 23, 2015, Pages 4108-4123

  Weiss, Sarah A ^a   Hanniford, Douglas ^a   Hernando, Eva ^a   Osman, Iman ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

biomarkers; genetics; melanoma; messenger RNA; microRNAs; prognostic; staging; tumor infiltrating lymphocytes

Indexed keywords

B RAF KINASE; C REACTIVE PROTEIN; CD24 ANTIGEN; CIRCULATING TUMOR DNA; DNA; HOMEOBOX A1; MESSENGER RNA; MICRORNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOPROTEIN PHOSPHATASE; PROTEIN PHOSPHATASE 6; PROTEIN TYROSINE KINASE; RAC1 PROTEIN; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTION FACTOR; TUMOR MARKER; UNCLASSIFIED DRUG; V KIT HARDY ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE;

BAP1 GENE; BRAF GENE; CANCER ADJUVANT THERAPY; CANCER EPIDEMIOLOGY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CD24 GENE; CLINICAL ASSESSMENT TOOL; CLINICAL FEATURE; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DISTANT METASTASIS FREE SURVIVAL; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; GENETIC MARKER; GENETIC VARIABILITY; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOREGULATION; LYMPH NODE METASTASIS; MELANOMA SKIN CANCER; MINICHROMOSOME; MISSENSE MUTATION; MITOSIS; NEXT GENERATION SEQUENCING; NRAS GENE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SELECTION; PPP6C GENE; PRIORITY JOURNAL; PTEN GENE; RAC1 GENE; REVIEW; TERT GENE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR VOLUME; ULCER; GENETICS; IMMUNOLOGY; MELANOMA; PATHOLOGY; PROGNOSIS; SKIN TUMOR; SURVIVAL ANALYSIS;

BIOMARKERS, TUMOR; HUMANS; MELANOMA; NEOPLASM STAGING; PROGNOSIS; SKIN NEOPLASMS; SURVIVAL ANALYSIS;

EID: 84948570123     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29634     Document Type: Review

References (118)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9-29.
2. Clark WH Jr, From L, Bernardino EA, Mihm MC. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res. 1969;29:705-727.
3. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg. 1970;172:902-908.
4. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635-3648.
5. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17, 600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19:3622-3634.
6. Buzaid AC, Ross MI, Balch CM, et al. Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol. 1997;15:1039-1051.
7. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27: 6199-6206.
8. Piris A, Mihm MC Jr, Duncan LM. AJCC melanoma staging update: impact on dermatopathology practice and patient management. J Cutan Pathol. 2011;38:394-400.
9. American Cancer Society. What are the survival rates for melanoma skin cancer, by stage? Available at: http://www.cancer.org/cancer/skincancer-melanoma/detailedguide/melanoma-skin-cancer-survivalrates. Accessed April 26, 2015.
10. Gimotty PA, Elder DE, Fraker DL, et al. Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. J Clin Oncol. 2007;25:1129-1134.
11. Balch CM, Gershenwald JE, Soong SJ, et al. Multivariate analysis of prognostic factors among 2313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol. 2010;28:2452-2459.
12. Harbst K, Staaf J, Lauss M, et al. Molecular profiling reveals lowand high-grade forms of primary melanoma. Clin Cancer Res. 2012; 18:4026-4036.
13. von Smolinski D, Leverkoehne I, von Samson-Himmelstjerna G, Gruber AD. Impact of formalin-fixation and paraffin-embedding on the ratio between mRNA copy numbers of differently expressed genes. Histochem Cell Biol. 2005;124:177-188.
14. Berger MF, Hodis E, Heffernan TP, et al. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature. 2012;485: 502-506.
15. Hodis E, Watson IR, Kryukov GV, et al. A landscape of driver mutations in melanoma. Cell. 2012;150:251-263.
16. Jeck WR, Parker J, Carson CC, et al. Targeted next generation sequencing identifies clinically actionable mutations in patients with melanoma. Pigment Cell Melanoma Res. 2014;27:653-663.
17. Krauthammer M, Kong Y, Ha BH, et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet. 2012;44:1006-1014.
18. Lawrence MS, Stojanov P, Mermel CH, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014; 505:495-501.
19. Jarkowski A, 3rd, Norris L, Trinh VA. Controversies in the management of advanced melanoma: "gray "areas amid the "black and blue. Ann Pharmacother. 2014;48:1456-1468.
20. Dong J, Phelps RG, Qiao R, et al. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res. 2003;63:3883-3885.
21. Safaee Ardekani G, Jafarnejad SM, Tan L, Saeedi A, Li G. The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-Analysis [serial online]. PLoS One. 2012;7:e47054.
22. Maldonado JL, Fridlyand J, Patel H, et al. Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst. 2003;95:1878-1890.
23. Ellerhorst JA, Greene VR, Ekmekcioglu S, et al. Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin Cancer Res. 2011;17:229-235.
24. Devitt B, Liu W, Salemi R, et al. Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. Pigment Cell Melanoma Res. 2011;24:666-672.
25. Akslen LA, Angelini S, Straume O, et al. BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival. J Invest Dermatol. 2005; 125:312-317.
26. Mann GJ, Pupo GM, Campain AE, Carter CD, Schramm SJ, Pianova S, Gerega SK, De Silva C, Lai K, Wilmott JS, et al. BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma. J Invest Dermatol. 2013;133:509-517.
27. Thomas NE, Edmiston SN, Alexander A, et al. Association between and mutational status and melanoma-specific survival among patients with higher risk primary melanoma. JAMA Oncol. 2015;1:359-368.
28. Shinozaki M, Fujimoto A, Morton DL, Hoon DS. Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin Cancer Res. 2004;10:1753-1757.
29. Woodman SE, Davies MA. Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics. Biochem Pharmacol. 2010;80:568-574.
30. Todd JR, Scurr LL, Becker TM, Kefford RF, Rizos H. The MAPK pathway functions as a redundant survival signal that reinforces the PI3K cascade in c-Kit mutant melanoma. Oncogene. 2014;33:236-245.
31. Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006;24:4340-4346.
32. Beadling C, Jacobson-Dunlop E, Hodi FS, et al. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res. 2008;14:6821-6828.
33. Bradford PT, Goldstein AM, McMaster ML, Tucker MA. Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986-2005. Arch Dermatol. 2009;145:427-434.
34. Mikhail M, Velazquez E, Shapiro R, et al. PTEN expression in melanoma: relationship with patient survival, Bcl-2 expression, and proliferation. Clin Cancer Res. 2005;11:5153-5157.
35. Aguissa-Doure AH, Li G. Genetic alterations of PTEN in human melanoma. Cell Mol Life Sci. 2012;69:1475-1491.
36. Lahtz C, Stranzenbach R, Fiedler E, Helmbold P, Dammann RH. Methylation of PTEN as a prognostic factor in malignant melanoma of the skin. J Invest Dermatol. 2010;130:620-622.
37. Gold HL, Wengrod J, de Miera EV, et al. PP6C hotspot mutations in melanoma display sensitivity to Aurora kinase inhibition. Mol Cancer Res. 2014;12:433-439.
38. Mar VJ, Wong SQ, Logan A, et al. Clinical and pathological associations of the activating RAC1 P29S mutation in primary cutaneous melanoma. Pigment Cell Melanoma Res. 2014;27:1117-1125.
39. Dutton-Regester K, Gartner JJ, Emmanuel R, et al. A highly recurrent RPS27 50UTR mutation in melanoma. Oncotarget. 2014;5: 2912-2917.
40. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA. Highly recurrent TERT promoter mutations in human melanoma. Science. 2013;339:957-959.
41. Horn S, Figl A, Rachakonda PS, et al. TERT promoter mutations in familial and sporadic melanoma. Science. 2013;339:959-961.
42. Griewank KG, Murali R, Puig-Butille JA, et al. TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma [serial online]. J Natl Cancer Inst. 2014;106:dju246.
43. Populo H, Boaventura P, Vinagre J, et al. TERT promoter mutations in skin cancer: the effects of sun exposure and X-irradiation. J Invest Dermatol. 2014;134:2251-2257.
44. Gould Rothberg BE, Berger AJ, Molinaro AM, et al. Melanoma prognostic model using tissue microarrays and genetic algorithms. J Clin Oncol. 2009;27:5772-5780.
45. Gould Rothberg BE, Bracken MB, Rimm DL. Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and metaanalysis. J Natl Cancer Inst. 2009;101:452-474.
46. Gould Rothberg BE, Rimm DL. Biomarkers: the useful and the not so useful-An assessment of molecular prognostic markers for cutaneous melanoma. J Invest Dermatol. 2010;130:1971-1987.
47. Rothberg BE, Rimm DL. Construction and analysis of multiparameter prognostic models for melanoma outcome. Methods Mol Biol. 2014;1102:227-258.
48. Meyer S, Fuchs TJ, Bosserhoff AK, et al. A 7-marker signature and clinical outcome in malignant melanoma: a large-scale tissue-microarray study with 2 independent patient cohorts [serial online]. PLoS One. 2012;7:e38222.
49. Kashani-Sabet M, Venna S, Nosrati M, et al. A multimarker prognostic assay for primary cutaneous melanoma. Clin Cancer Res. 2009;15:6987-6992.
50. Klopfleisch R, Weiss A, Gruber A. Excavation of a buried treasure-DNA, mRNA, miRNA and protein analysis in formalin fixed, paraffin embedded tissues. Histol Histopathol. 2011;26:797-1607.
51. Jaeger J, Koczan D, Thiesen HJ, et al. Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in lasermicrodissected melanoma tissues. Clin Cancer Res. 2007;13:806-815.
52. Bittner M, Meltzer P, Chen Y, et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature. 2000;406:536-540.
53. Haqq C, Nosrati M, Sudilovsky D, et al. The gene expression signatures of melanoma progression. Proc Natl Acad Sci U S A. 2005;102: 6092-6097.
54. Talantov D, Mazumder A, Yu J, et al. Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clin Cancer Res. 2005;11:7234-7276.
55. Riker A, Enkemann S, Fodstad O, et al. The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis [serial online]. BMC Med Genomics. 2008;1:13.
56. Winnepenninckx V, Lazar V, Michiels S, et al. Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst. 2006;98:472-482.
57. Brunner G, Reitz M, Schwipper V, et al. Increased expression of the tumor suppressor PLZF is a continuous predictor of long-Derm survival in malignant melanoma patients. Cancer Biother Radiopharm. 2008;23:451-459.
58. Brunner G, Reitz M, Heinecke A, et al. A 9-gene signature predicting clinical outcome in cutaneous melanoma. J Cancer Res. Clin Oncol. 2013;139:249-258.
59. Gschaider M, Neumann F, Peters B, et al. An attempt at a molecular prediction of metastasis in patients with primary cutaneous melanoma [serial online]. PLoS One. 2012;7:e49865.
60. Gerami P, Cook RW, Russell MC, et al. Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy. J Am Acad Dermatol. 2015;72:780.e3-785.e3.
61. Gerami P, Cook RW, Wilkinson J, et al. Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma. Clin Cancer Res. 2015;21:175-183.
62. Wardwell-Ozgo J, Dogruluk T, Gifford A, et al. HOXA1 drives melanoma tumor growth and metastasis and elicits an invasion gene expression signature that prognosticates clinical outcome. Oncogene. 2014;33:1017-1026.
63. Sivendran S, Chang R, Pham L, et al. Dissection of immune gene networks in primary melanoma tumors critical for antitumor surveillance of patients with stage II-III resectable disease. J Invest Dermatol. 2014;134:2202-2211.
64. Hanniford D, Segura MF, Zhong J, et al. Identification of metastasis-suppressive microRNAs in primary melanoma [serial online]. J Natl Cancer Inst. 2015;107:dju4944.
65. Hanniford D, Zhong J, Koetz L, et al. A miRNA-based signature detected in primary melanoma tissue predicts development of brain metastasis [published online ahead of print June 18, 2015]. Clin Cancer Res. doi: clincanres.2566.2014.
66. Poliseno L, Haimovic A, Segura MF, et al. Histology-specific micro-RNA alterations in melanoma. J Invest Dermatol. 2012;132:1860-1868.
67. van Kempen LC, van den Hurk K, Lazar V, et al. Loss of microRNA-200a and c, and microRNA-203 expression at the invasive front of primary cutaneous melanoma is associated with increased thickness and disease progression. Virchows Arch. 2012;461:441-448.
68. Gaziel-Sovran A, Segura M, Di Micco R, et al. miR-30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis. Cancer Cell. 2011;20:104-122.
69. Pencheva N, Tran H, Buss C, et al. Convergent multi-miRNA targeting of ApoE drives LRP1/LRP8-dependent melanoma metastasis and angiogenesis. Cell. 2012;151:1068-1082.
70. Satzger I, Mattern A, Kuettler U, et al. MicroRNA-15b represents an independent prognostic parameter and is correlated with tumor cell proliferation and apoptosis in malignant melanoma. J Int Cancer. 2010;126:2553-2615.
71. Kauffmann A, Rosselli F, Lazar V, et al. High expression of DNA repair pathways is associated with metastasis in melanoma patients. Oncogene. 2008;27:565-573.
72. Conway C, Mitra A, Jewell R, et al. Gene expression profiling of paraffin-embedded primary melanoma using the DASL assay identifies increased osteopontin expression as predictive of reduced relapsefree survival. Clin Cancer Res. 2009;15:6939-6946.
73. Rangel J, Nosrati M, Torabian S, et al. Osteopontin as a molecular prognostic marker for melanoma. Cancer. 2008;112:144-150.
74. Zhou Y, Dai DL, Martinka M, et al. Osteopontin expression correlates with melanoma invasion. J Invest Dermatol. 2005;124:1044-1052.
75. Jewell R, Conway C, Mitra A, et al. Patterns of expression of DNA repair genes and relapse from melanoma. Clin Cancer Res. 2010;16: 5211-5221.
76. Hall JS, Taylor J, Valentine HR, et al. Enhanced stability of micro-RNA expression facilitates classification of FFPE tumour samples exhibiting near total mRNA degradation. Br J Cancer. 2012;107: 684-694.
77. Xi Y, Nakajima G, Gavin E, et al. Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA. 2007;13:1668-1674.
78. Caramuta S, Egyh-Azi S, Rodolfo M, et al. MicroRNA expression profiles associated with mutational status and survival in malignant melanoma. J Invest Dermatol. 2010;130:2062-2132.
79. Chen J, Feilotter H, Par-e G, et al. MicroRNA-193b represses cell proliferation and regulates cyclin D1 in melanoma. Am J Pathol. 2010;176:2520-2529.
80. Mazar J, DeYoung K, Khaitan D, et al. The regulation of miRNA-211 expression and its role in melanoma cell invasiveness [serial online]. PLoS One. 2010;5:e13779.
81. Philippidou D, Schmitt M, Moser D, et al. Signatures of micro-RNAs and selected microRNA target genes in human melanoma. Cancer Res. 2010;70:4163-4236.
82. Levy C, Khaled M, Iliopoulos D, et al. Intronic miR-211 assumes the tumor suppressive function of its host gene in melanoma. Mol Cell. 2010;40:841-849.
83. Segura M, Belitskaya-Levy I, Rose A, et al. Melanoma MicroRNA signature predicts post-recurrence survival. Clin Cancer Res. 2010;16: 1577-1663.
84. Tembe V, Schramm SJ, Stark MS, et al. MicroRNA and mRNA expression profiling in metastatic melanoma reveal associations with BRAF mutation and patient prognosis. Pigment Cell Melanoma Res. 2015;28:254-266.
85. Boyle GM, Woods SL, Bonazzi VF, et al. Melanoma cell invasiveness is regulated by miR-211 suppression of the BRN2 transcription factor. Pigment Cell Melanoma Res. 2011;24:525-562.
86. Galon J, Pages F, Marincola FM, et al. Cancer classification using the Immunoscore: a worldwide task force [serial online]. J Transl Med. 2012;10:205.
87. Clark WH Jr, Elder DE, Guerry D 4th, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst. 1989;81:1893-1904.
88. Barnhill RL, Fine JA, Roush GC, Berwick M. Predicting 5-year outcome for patients with cutaneous melanoma in a population-based study. Cancer. 1996;78:427-432.
89. Clemente CG, Mihm MC Jr, Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer. 1996;77:1303-1310.
90. Tuthill RJ, Unger JM, Liu PY, Flaherty LE, Sondak VK. Risk assessment in localized primary cutaneous melanoma: a Southwest Oncology Group study evaluating 9 factors and a test of the Clark logistic regression prediction model. Am J Clin Pathol. 2002;118:504-511.
91. Taylor RC, Patel A, Panageas KS, Busam KJ, Brady MS. Tumorinfiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. J Clin Oncol. 2007;25:869-875.
92. Mandala M, Imberti GL, Piazzalunga D, et al. Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database. Eur J Cancer. 2009;45:2537-2545.
93. Burton AL, Roach BA, Mays MP, et al. Prognostic significance of tumor infiltrating lymphocytes in melanoma. Am Surg. 2011;77:188-192.
94. Azimi F, Scolyer RA, Rumcheva P, et al. Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol. 2012;30:2678-2683.
95. Thomas NE, Busam KJ, From L, et al. Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study. J Clin Oncol. 2013;31: 4252-4259.
96. Fortes C, Mastroeni S, Manooranparanpampil T, et al. Tumor-infiltrating lymphocytes predict cutaneous melanoma survival [serial online]. J Transl Med. 2015;13(suppl 1):O9.
97. Rao UN, Lee SJ, Luo W, Mihm MC Jr, Kirkwood JM. Presence of tumor-infiltrating lymphocytes and a dominant nodule within primary melanoma are prognostic factors for relapse-free survival of patients with thick (T4) primary melanoma: pathologic analysis of the e1690 and e1694 intergroup trials. Am J Clin Pathol. 2010;133:646-653.
98. Capone M. Immunoscore: a new possible approach for melanoma classification [serial online]. J Immunother Cancer. 2014;2(suppl3):P193.
99. Erdag G, Schaefer JT, Smolkin ME, et al. Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res. 2012;72:1070-1080.
100. Cancer Genome Atlas Network. Genomic Classification of Cutaneous Melanoma. Cell. 2015;161:1681-1696.
101. Sandru A, Panaitescu E, Voinea S, et al. Prognostic value of melanoma inhibitory activity protein in localized cutaneous malignant melanoma [serial online]. J Skin Cancer. 2014;2014:843214.
102. Martenson ED, Hansson LO, Nilsson B, et al. Serum S-100b protein as a prognostic marker in malignant cutaneous melanoma. J Clin Oncol. 2001;19:824-831.
103. Bonfrer JM, Korse CM, Nieweg OE, Rankin EM. The luminescence immunoassay S-100: a sensitive test to measure circulating S-100B: its prognostic value in malignant melanoma. Br J Cancer. 1998;77:2210-2214.
104. Deichmann M, Kahle B, Moser K, Wacker J, Wust K. Diagnosing melanoma patients entering American Joint Committee on Cancer stage IV, C-reactive protein in serum is superior to lactate dehydrogenase. Br J Cancer. 2004;91:699-702.
105. Fang S, Wang Y, Sui D, et al. C-reactive protein as a marker of melanoma progression. J Clin Oncol. 2015;33:1389-1396.
106. Fleming NH, Zhong J, da Silva IP, et al. Serum-based miRNAs in the prediction and detection of recurrence in melanoma patients. Cancer. 2015;121:51-59.
107. Friedman EB, Shang S, de Miera EV, et al. Serum microRNAs as biomarkers for recurrence in melanoma [serial online]. J Transl Med. 2012;10:155.
108. Lipson EJ, Velculescu VE, Pritchard TS, et al. Circulating tumor DNA analysis as a real-Dime method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade. J Immunother Cancer. 2014;2:42.
109. Sanmamed MF, Fernandez-Landazuri S, Rodriguez C, et al. Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors. Clin Chem. 2015; 61:297-304.
110. Ellis CM, Dyson MJ, Stephenson TJ, Maltby EL. HER2 amplification status in breast cancer: a comparison between immunohistochemical staining and fluorescence in situ hybridisation using manual and automated quantitative image analysis scoring techniques. J Clin Pathol. 2005;58:710-714.
111. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347:1999-2009.
112. Cronin M, Sangli C, Liu ML, et al. Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptorpositive breast cancer. Clin Chem. 2007;53:1084-1091.
113. Webber EM, Lin JS, Whitlock EP. Oncotype DX tumor gene expression profiling in stage II colon cancer. Application: prognostic, risk prediction [serial online]. PLoS Curr. 2010;2:RRN1177.
114. Castle Biosciences. DecisionDx-Melanoma Test. Test overview: identifying early stage melanomas at high risk of metastasis. Available at: http://skinmelanoma.com/decisiondx-melanoma-Dest/testoverview-value/. Accessed June 18, 2015.
115. McShane LM, Altman DG, Sauerbrei W, et al. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol. 2005;23:9067-9072.
116. Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration [serial online]. PLoS Med. 2012;9:e1001216.
117. Greenwald HS, Friedman EB, Osman I. Superficial spreading and nodular melanoma are distinct biological entities: a challenge to the linear progression model. Melanoma Res. 2012;22:1-8.
118. Warycha MA, Christos PJ, Mazumdar M, et al. Changes in the presentation of nodular and superficial spreading melanomas over 35 years. Cancer. 2008;113:3341-3348.